vs

Side-by-side financial comparison of ELECTRO SENSORS INC (ELSE) and INVO Fertility, Inc. (IVF). Click either name above to swap in a different company.

ELECTRO SENSORS INC is the larger business by last-quarter revenue ($2.8M vs $1.8M, roughly 1.6× INVO Fertility, Inc.). ELECTRO SENSORS INC runs the higher net margin — 3.7% vs -150.5%, a 154.2% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs 14.8%). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs 10.8%).

Polar Electro Oy is a Finnish manufacturer of sports training computers, particularly known for developing the world's first wireless heart rate monitor.

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

ELSE vs IVF — Head-to-Head

Bigger by revenue
ELSE
ELSE
1.6× larger
ELSE
$2.8M
$1.8M
IVF
Growing faster (revenue YoY)
IVF
IVF
+7.8% gap
IVF
22.6%
14.8%
ELSE
Higher net margin
ELSE
ELSE
154.2% more per $
ELSE
3.7%
-150.5%
IVF
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
10.8%
ELSE

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ELSE
ELSE
IVF
IVF
Revenue
$2.8M
$1.8M
Net Profit
$103.0K
$-2.6M
Gross Margin
50.3%
Operating Margin
-0.3%
-93.1%
Net Margin
3.7%
-150.5%
Revenue YoY
14.8%
22.6%
Net Profit YoY
-48.8%
-62.2%
EPS (diluted)
$0.03
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ELSE
ELSE
IVF
IVF
Q4 25
$2.8M
Q3 25
$2.7M
$1.8M
Q2 25
$2.4M
$1.9M
Q1 25
$2.2M
$1.6M
Q4 24
$2.4M
$1.7M
Q3 24
$2.5M
$1.4M
Q2 24
$2.2M
$1.8M
Q1 24
$2.2M
$1.6M
Net Profit
ELSE
ELSE
IVF
IVF
Q4 25
$103.0K
Q3 25
$208.0K
$-2.6M
Q2 25
$59.0K
$-5.3M
Q1 25
$-64.0K
$-17.4M
Q4 24
$201.0K
$-3.6M
Q3 24
$238.0K
$-1.6M
Q2 24
$-4.0K
$-2.2M
Q1 24
$11.0K
$-1.6M
Gross Margin
ELSE
ELSE
IVF
IVF
Q4 25
50.3%
Q3 25
53.1%
Q2 25
51.2%
Q1 25
48.4%
35.2%
Q4 24
49.6%
41.4%
Q3 24
50.4%
31.0%
Q2 24
47.2%
53.1%
Q1 24
48.1%
45.3%
Operating Margin
ELSE
ELSE
IVF
IVF
Q4 25
-0.3%
Q3 25
6.6%
-93.1%
Q2 25
-0.1%
-160.4%
Q1 25
-7.5%
-1042.1%
Q4 24
1.3%
-202.0%
Q3 24
6.9%
-90.7%
Q2 24
-4.8%
-100.9%
Q1 24
-4.5%
-95.7%
Net Margin
ELSE
ELSE
IVF
IVF
Q4 25
3.7%
Q3 25
7.6%
-150.5%
Q2 25
2.5%
-283.6%
Q1 25
-2.9%
-1060.1%
Q4 24
8.4%
-211.3%
Q3 24
9.5%
-113.8%
Q2 24
-0.2%
-122.2%
Q1 24
0.5%
-101.3%
EPS (diluted)
ELSE
ELSE
IVF
IVF
Q4 25
$0.03
Q3 25
$0.06
$-0.77
Q2 25
$0.02
$-13.30
Q1 25
$-0.02
$-12.53
Q4 24
$0.06
$14.86
Q3 24
$0.07
$-15.11
Q2 24
$0.00
$-22.39
Q1 24
$0.00
$-7.55

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ELSE
ELSE
IVF
IVF
Cash + ST InvestmentsLiquidity on hand
$10.6M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$14.8M
$5.8M
Total Assets
$15.7M
$18.8M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ELSE
ELSE
IVF
IVF
Q4 25
$10.6M
Q3 25
$10.6M
Q2 25
$10.2M
Q1 25
$10.0M
Q4 24
$10.0M
Q3 24
$10.3M
Q2 24
$9.9M
Q1 24
$10.1M
Total Debt
ELSE
ELSE
IVF
IVF
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ELSE
ELSE
IVF
IVF
Q4 25
$14.8M
Q3 25
$14.7M
$5.8M
Q2 25
$14.4M
$2.6M
Q1 25
$14.3M
$3.3M
Q4 24
$14.3M
$12.7M
Q3 24
$14.1M
$-23.3K
Q2 24
$13.8M
$1.4M
Q1 24
$13.8M
$10.2K
Total Assets
ELSE
ELSE
IVF
IVF
Q4 25
$15.7M
Q3 25
$15.7M
$18.8M
Q2 25
$15.2M
$19.3M
Q1 25
$15.1M
$31.7M
Q4 24
$14.9M
$46.4M
Q3 24
$15.0M
$17.0M
Q2 24
$14.5M
$17.8M
Q1 24
$14.5M
$17.3M
Debt / Equity
ELSE
ELSE
IVF
IVF
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ELSE
ELSE
IVF
IVF
Operating Cash FlowLast quarter
$20.0K
$-1.8M
Free Cash FlowOCF − Capex
$-1.8M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
0.19×
TTM Free Cash FlowTrailing 4 quarters
$-7.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ELSE
ELSE
IVF
IVF
Q4 25
$20.0K
Q3 25
$395.0K
$-1.8M
Q2 25
$277.0K
$-1.7M
Q1 25
$-30.0K
$-3.5M
Q4 24
$-277.0K
$-617.4K
Q3 24
$362.0K
$-640.8K
Q2 24
$-158.0K
$-1.5M
Q1 24
$202.0K
$-260.6K
Free Cash Flow
ELSE
ELSE
IVF
IVF
Q4 25
Q3 25
$389.0K
$-1.8M
Q2 25
$-1.7M
Q1 25
$-3.6M
Q4 24
$-298.0K
$-696.3K
Q3 24
$358.0K
Q2 24
$-184.0K
$-1.5M
Q1 24
$-310.3K
FCF Margin
ELSE
ELSE
IVF
IVF
Q4 25
Q3 25
14.2%
-101.6%
Q2 25
-92.6%
Q1 25
-216.9%
Q4 24
-12.4%
-40.6%
Q3 24
14.3%
Q2 24
-8.3%
-82.3%
Q1 24
-19.7%
Capex Intensity
ELSE
ELSE
IVF
IVF
Q4 25
Q3 25
0.2%
0.5%
Q2 25
0.5%
Q1 25
0.9%
Q4 24
0.9%
4.6%
Q3 24
0.2%
0.0%
Q2 24
1.2%
3.0%
Q1 24
0.0%
3.2%
Cash Conversion
ELSE
ELSE
IVF
IVF
Q4 25
0.19×
Q3 25
1.90×
Q2 25
4.69×
Q1 25
Q4 24
-1.38×
Q3 24
1.52×
Q2 24
Q1 24
18.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons